# Pfizer: Observational study closed enrollment, 350 enrolled (Transthyretin Amyloid Cardiopathy)

**Score:** 60/100

| Field | Value |
|---|---|
| Sponsor | Pfizer |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | ATTR-CM: A Multi-country, Non-interventional Disease Registry |
| NCT ID | NCT06651073 |
| Phase | Observational |
| Status | active not recruiting |
| Conditions | Transthyretin Amyloid Cardiopathy |
| Intervention types | other |
| Target enrollment | 350 |
| Site countries | Hong Kong, Malaysia, Taiwan |
| Posted | 2024-10-21 |
| Planned start | 2024-10-01 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-06 |
| Last update posted | 2026-10-06 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- 350 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06651073). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.